Dworkin Robert H, Anderson Brian T, Andrews Nick, Edwards Robert R, Grob Charles S, Ross Stephen, Satterthwaite Theodore D, Strain Eric C
Departments of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Center for Health + Technology, University of Rochester School of Medicine and Dentistry, Rochester, New York.
Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for the Neurosciences and Zuckerberg San Francisco General Hospital, San Francisco, CA, United States, and UC Berkeley Center for the Science of Psychedelics, Berkeley, California.
J Pain. 2022 Oct;23(10):1666-1679. doi: 10.1016/j.jpain.2022.05.003. Epub 2022 May 25.
Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of consciousness has been described throughout recorded history. Accounts of the subjective effects of psychedelics typically focus on spiritual and mystical-type experiences, including feelings of unity, sacredness, and transcendence. Over the past 2 decades, there has been increasing interest in psychedelics as treatments for various medical disorders, including chronic pain. Although concerns about adverse medical and psychological effects contributed to their controlled status, contemporary knowledge of psychedelics suggests that risks are relatively rare when patients are carefully screened, prepared, and supervised. Clinical trial results have provided support for the effectiveness of psychedelics in different psychiatric conditions. However, there are only a small number of generally uncontrolled studies of psychedelics in patients with chronic pain (eg, cancer pain, phantom limb pain, migraine, and cluster headache). Challenges in evaluating psychedelics as treatments for chronic pain include identifying neurobiologic and psychosocial mechanisms of action and determining which pain conditions to investigate. Truly informative proof-of-concept and confirmatory randomized clinical trials will require careful selection of control groups, efforts to minimize bias from unblinding, and attention to the roles of patient mental set and treatment setting. PERSPECTIVE: There is considerable promise for the use of psychedelic therapy for pain, but evidence-based recommendations for the design of future studies are needed to ensure that the results of this research are truly informative.
迷幻物质在不同文化中都发挥了重要作用,并且在有记录的历史中,人们一直描述通过摄入各种植物制剂来引发意识状态的改变。关于迷幻剂主观效果的描述通常集中在精神和神秘主义类型的体验上,包括合一感、神圣感和超越感。在过去的20年里,人们对迷幻剂作为治疗各种医学疾病(包括慢性疼痛)的方法越来越感兴趣。尽管对不良医学和心理影响的担忧导致它们处于受控状态,但当代对迷幻剂的了解表明,在对患者进行仔细筛选、准备和监督的情况下,风险相对较少。临床试验结果为迷幻剂在不同精神疾病中的有效性提供了支持。然而,针对慢性疼痛患者(如癌症疼痛、幻肢痛、偏头痛和丛集性头痛)使用迷幻剂的一般性非对照研究仅有少数。将迷幻剂评估为慢性疼痛治疗方法面临的挑战包括确定神经生物学和社会心理作用机制,以及确定要研究哪些疼痛病症。真正有信息量的概念验证和确证性随机临床试验将需要仔细选择对照组,努力将非盲法导致的偏倚降至最低,并关注患者心理状态和治疗环境的作用。观点:迷幻剂疗法用于治疗疼痛有很大前景,但需要基于证据的未来研究设计建议,以确保这项研究的结果真正具有信息量。